FI965153A0 - Metalloproteinase inhibitors - Google Patents

Metalloproteinase inhibitors

Info

Publication number
FI965153A0
FI965153A0 FI965153A FI965153A FI965153A0 FI 965153 A0 FI965153 A0 FI 965153A0 FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A FI 965153 A0 FI965153 A0 FI 965153A0
Authority
FI
Finland
Prior art keywords
metalloproteinase inhibitors
compounds
inhibitors
medicine
processes
Prior art date
Application number
FI965153A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI965153A (en
Inventor
Andrew Miller
Mark Whittaker
Raymond Paul Beckett
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412514A external-priority patent/GB9412514D0/en
Priority claimed from GBGB9506107.3A external-priority patent/GB9506107D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of FI965153A0 publication Critical patent/FI965153A0/en
Publication of FI965153A publication Critical patent/FI965153A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Therapeutically active hydroxamic acid derivatives, processes for their preparation, pharmaceutical compositions containing them, and the use of such compounds in medicine. The compounds are inhibitors of metalloproteinases involved in tissue degradation.
FI965153A 1994-06-22 1996-12-20 metalloproteinase FI965153A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412514A GB9412514D0 (en) 1994-06-22 1994-06-22 Metalloproteinase inhibitors
GBGB9506107.3A GB9506107D0 (en) 1995-03-24 1995-03-24 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
FI965153A0 true FI965153A0 (en) 1996-12-20
FI965153A FI965153A (en) 1996-12-20

Family

ID=26305102

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965153A FI965153A (en) 1994-06-22 1996-12-20 metalloproteinase

Country Status (17)

Country Link
US (4) US5962529A (en)
EP (2) EP0766664B1 (en)
JP (2) JPH10501806A (en)
CN (1) CN1151157A (en)
AT (2) ATE182581T1 (en)
AU (2) AU690703B2 (en)
CA (2) CA2193691A1 (en)
DE (2) DE69511089T2 (en)
DK (2) DK0766665T3 (en)
ES (2) ES2145913T3 (en)
FI (1) FI965153A (en)
GB (2) GB2303629B (en)
GR (2) GR3031143T3 (en)
NO (1) NO965515L (en)
NZ (2) NZ288298A (en)
PT (1) PT766664E (en)
WO (2) WO1995035276A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
NZ288298A (en) * 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR980009238A (en) 1995-07-28 1998-04-30 우에노 도시오 Sulfonyl amino acid derivative
ATE226936T1 (en) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co HYDROXAMIC ACID DERIVATIVES USABLE FOR INHIBITING GELATINASE
ATE213232T1 (en) † 1995-11-13 2002-02-15 Hoechst Ag CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
PT874830E (en) * 1995-12-08 2003-06-30 Agouron Pharma METHYLOPROTEINAS INHIBITOR PHARMACEUTICAL COMPOSITION CONTAINING THIS INHIBITOR AND THE PHARMACEUTICAL UTILIZATION AND USEFUL METHOD FOR THEIR PREPARATION
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
PL205341B1 (en) * 1996-01-23 2010-04-30 Shionogi & Co Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
FR2748026B1 (en) * 1996-04-26 1998-06-05 Adir NOVEL METALLOPROTEASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SK282863B6 (en) * 1996-05-17 2002-12-03 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
AU3729397A (en) * 1996-08-16 1998-03-06 Warner-Lambert Company Butyric acid matrix metalloproteinase inhibitors
US6153609A (en) * 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1998008823A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
NZ334258A (en) * 1996-08-28 2000-11-24 Procter & Gamble Phosphinic acid amides as matrix metalloprotease inhibitors
EP0925287B1 (en) * 1996-08-28 2003-01-15 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
TR199900429T2 (en) * 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metalloproteaz inhibit�rleri.
PL331838A1 (en) * 1996-08-28 1999-08-02 Procter & Gamble 1,3-diheterocyclic inhibitors of metaloproteases
BR9712792A (en) * 1996-08-28 1999-12-14 Procter & Gamble Bidentate metalloprotease inhibitors.
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
DK0938471T3 (en) * 1996-10-16 2002-01-28 American Cyanamid Co The preparation and use of ortho-sulfonamido-aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001503400A (en) * 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー Α-Aminosulfonylhydroxamic acids as matrix metalloproteinase inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
AU5426398A (en) 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AU720615B2 (en) * 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
EP0977745B1 (en) * 1997-03-04 2004-12-01 Pharmacia Corporation Thioaryl sulfonamide hydroxamic acid compounds
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
NZ338082A (en) * 1997-04-01 2000-06-23 Agouron Pharma Metalloproteinase and Tumor Necrosis Factor-alpha convertase inhibitors, pharmaceutical compositions and their use in treating disease mediated by metalloproteinase activity.
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (en) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarboxylic acids
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
PT877019E (en) * 1997-05-09 2002-05-31 Hoechst Ag SUBSTITUTED DIAMINOCARBOXYLIC ACIDS
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
TR200000214T2 (en) 1997-07-22 2000-09-21 Shionogi & Co., Ltd. Composition for the treatment or prevention of glomerulpathy.
KR100352316B1 (en) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
ES2176913T3 (en) * 1997-08-08 2002-12-01 Pfizer Prod Inc DERIVATIVES OF ARILSULFONYLAMINOHYDROXAMIC ACIDS.
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
TR200002224T2 (en) 1998-02-04 2000-12-21 Novartis Ag Sulfonylamino derivatives that inhibit matrix-disrupting metalloproteinases.
TR200002423T2 (en) * 1998-02-19 2001-01-22 American Cyanamid Company Matrix metalloproteinase inhibitors.
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
KR100615345B1 (en) 1998-07-16 2006-08-25 사노피-아벤티스 도이칠란트 게엠베하 Phosphinous and phosphonic acid derivatives used as medicaments, and pharmaceutical compositions containing the same
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
DE19851184A1 (en) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-arylsulfonylamino acid omega amides
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
EP1147085B1 (en) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
BR0009244A (en) 1999-03-03 2002-04-16 Procter & Gamble Diheter metalloprotease inhibitors replaced
IL145089A0 (en) 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
ES2200783T3 (en) 1999-03-31 2004-03-16 Pfizer Products Inc. HYDROXAMIC DIOXOCICLOPENTIL ACIDS.
KR20020027635A (en) 1999-09-10 2002-04-13 폴락 돈나 엘. Tyrosine kinase inhibitors
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
KR100733752B1 (en) 1999-11-26 2007-06-29 시오노기세이야쿠가부시키가이샤 Npyy5 antagonists
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
CA2404131A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
WO2001070693A2 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
CA2403778A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
PL357250A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
US6495358B1 (en) 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
EP1309579B1 (en) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibitors of matrix metalloproteinases
PT1373262E (en) * 2001-03-14 2010-07-26 Novartis Ag Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors
MXPA03010328A (en) 2001-05-11 2004-02-17 Guilford Pharm Inc Hydroxamic acids and acyl hydroxamines as naaladase inhibitors.
ES2255621T3 (en) 2001-06-22 2006-07-01 MERCK & CO., INC. THYROSINE KINASE INHIBITORS.
BR0213736A (en) 2001-11-01 2004-10-19 Wyeth Corp allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2003233154A1 (en) 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US7928127B2 (en) 2005-05-19 2011-04-19 Notre Dame University Inhibitors of matrix metallaproteinases
EA201100187A1 (en) * 2008-07-14 2011-10-31 Новартис Аг SELECTIVE INHIBITORS MMP-12 and MMP-13 BASED ON HYDROXAMIC ACID
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
AU2011306398A1 (en) 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4885027A (en) * 1985-04-05 1989-12-05 Chevron Research Company Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
HUT56050A (en) * 1987-12-18 1991-07-29 Schering Corp Process for resolving 2-amino-4phenyl-butane
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
HUT61973A (en) * 1990-12-03 1993-03-29 Celltech Ltd Process for producing peptidyl derivatives and pharmaceutical compositions comprising such compounds as active ingredient
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
NZ288298A (en) * 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
SK282863B6 (en) * 1996-05-17 2002-12-03 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US6124329A (en) 2000-09-26
DE69516143T2 (en) 2000-10-19
EP0766665B1 (en) 1999-07-28
NO965515L (en) 1997-02-20
GB9623675D0 (en) 1997-01-08
DE69511089T2 (en) 1999-12-16
GR3031143T3 (en) 1999-12-31
NZ288299A (en) 1998-06-26
US5962529A (en) 1999-10-05
DK0766664T3 (en) 2000-07-31
CA2193692A1 (en) 1995-12-28
AU690703B2 (en) 1998-04-30
DK0766665T3 (en) 1999-12-06
AU2746595A (en) 1996-01-15
AU2746695A (en) 1996-01-15
PT766664E (en) 2000-08-31
JPH10501806A (en) 1998-02-17
AU695507B2 (en) 1998-08-13
CN1151157A (en) 1997-06-04
GB2303850B (en) 1998-06-10
NZ288298A (en) 1998-12-23
ATE182581T1 (en) 1999-08-15
WO1995035276A1 (en) 1995-12-28
NO965515D0 (en) 1996-12-20
ES2133785T3 (en) 1999-09-16
GR3033446T3 (en) 2000-09-29
GB2303629B (en) 1998-09-02
EP0766664B1 (en) 2000-04-05
ATE191468T1 (en) 2000-04-15
GB2303850A (en) 1997-03-05
CA2193691A1 (en) 1995-12-28
ES2145913T3 (en) 2000-07-16
US6124332A (en) 2000-09-26
GB2303629A (en) 1997-02-26
GB9623809D0 (en) 1997-01-08
EP0766665A2 (en) 1997-04-09
EP0766664A2 (en) 1997-04-09
DE69516143D1 (en) 2000-05-11
JPH10507158A (en) 1998-07-14
DE69511089D1 (en) 1999-09-02
FI965153A (en) 1996-12-20
WO1995035275A1 (en) 1995-12-28
US6022898A (en) 2000-02-08

Similar Documents

Publication Publication Date Title
DE69516143D1 (en) METALLOPROTEINASE INHIBITORS
SE9402431D0 (en) New tablet formulation
TR199801180T2 (en) New compounds with analgesic effect.
BR9406363A (en) Pharmaceutical composition process for the preparation of the same use and process for the treatment of diseases related to gastric acid
NO20051966L (en) New pyrimidinamide derivatives and their use
UA50719C2 (en) Precursor for therapy of cancer and inflammation
AR023366A1 (en) USE OF N-CARBOXIMETABLE BENZOLACTAMES REPLACED FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE INHIBITION OF THE METALOPROTEINAS OF THE MATRIX, PARATRATATION OF A STATE OF NEOPLASIC DISEASE, FOR THE TREATMENT OF ATEROSCLEROSIS, FOR THE TREATMENT OF A INFRINGEMENT
ATE253359T1 (en) ANTITHRBOTIC AGENTS
TR199801184T2 (en) New compounds with analgesic action.
ATE286395T1 (en) ANTITHRBOTIC AGENTS
FI932654A (en) Hydroxamsyraderivat, som hindrar lipoxigenas
ES2194899T3 (en) PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION OF THE MORFINA-6-GLUCURONIDO ACTIVE PRINCIPLE.
TR200003451T2 (en) Pyrimidine-Aminomethyl-Pyridine Derivatives, Their Preparation and Their Use in the Control of Helicobacter Bacteria
DE69910787D1 (en) NEW, ACTIVE PHARMACEUTICAL CONNECTION
NO20001846L (en) New pharmaceutically active compounds, their preparation and use as ECE inhibitors
ATE268768T1 (en) ANTITHROMBOTIC AGENTS
ATE109981T1 (en) THERAPEUTIC REMEDIES.
JO1881B1 (en) Multiple unit tableted dosage from ii
IT1255678B (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS OR RECTAL RELATED PEPTIDES.
MX9503130A (en) Metaloproteinase inhibitors, process for their preparation and pharmaceutical or veterinarian compositions containing them.